Table 1 Demographics and clinical characteristics of women with metastatic breast cancer depending on physical activity level.

From: Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer

 

Total physical activity (MET-hours/week)

Total N = 833

Light physical activity (< 10 MET-hour/week)

N = 97 (12%)

Moderate physical activity ([10;50[ MET-hour/week)

N = 575 (69%)

Vigorous physical activity (≥ 50 MET-hour/week)

N = 161 (19%)

Demographic

Age at primitive tumor diagnosis

 N

97

573

161

 

 Mean ± sd

62.4 (± 12.0)

52.1 (± 12.8)

50.8 (± 11.1)

53.1 (± 12.8)

Age at metastatic diagnosis

 N

97

575

161

 

 Mean ± sd

67.2 (± 11.6)

56.9 (± 13.1)

55.7 (± 11.4)

57.8 (± 13.1)

Weight, kg

N

97

572

161

830

 Mean ± sd

69.5 (± 16.6)

68.3 (± 14.7)

64.6 (± 12.9)

67.7 (± 14.7)

Missing data

0

3

0

3

Body mass index, kg/m

 Underweight (< 18.5 kg/m2)

6 (6.2%)

18 (3.2%)

7 (4.3%)

31 (3.7%)

 Normal weight (< 25 kg/m2)

36 (37.1%)

274 (48.0%)

91 (56.5%)

401 (48.4%)

 Overweight (25–30 kg/m2)

27 (27.8%)

163 (28.5%)

44 (27.3%)

234 (28.2%)

 Obese (> 30 kg/m2)

28 (28.9%)

116 (20.3%)

19 (11.8%)

163 (19.7%)

 Missing data

0

4

0

4

PS ECOG

 0–1

55 (70.5%)

413 (90.8%)

128 (93.4%)

596 (89.0%)

 2–3

23 (29.5%)

42 (9.2%)

9 (6.6%)

74 (11.0%)

 Missing data

19

120

24

163

Metastatic at diagnosis

 No

54 (55.7%)

363 (63.5%)

104 (64.6%)

521 (62.8%)

 Yes

31 (32.0%)

136 (23.8%)

37 (23.0%)

204 (24.6%)

 Undetermined

12 (12.4%)

73 (12.8%)

20 (12.4%)

105 (12.7%)

 Missing data

0

3

0

3

Education

 High School

64 (73.6%)

274 (51.1%)

65 (43.3%)

403 (52.1%)

 1- to 2-year university degree

17 (19.5%)

156 (29.1%)

48 (32.0%)

221 (28.6%)

 > 2-year university degree

6 (6.9%)

106 (19.8%)

37 (24.7%)

149 (19.3%)

 Missing data

10

39

11

60

Smokers

 Yes

26 (27.4%)

255 (44.8%)

67 (41.6%)

348 (42.2%)

 No

69 (72.6%)

314 (55.2%)

94 (58.4%)

477 (57.8%)

 Missing data

2

6

0

8

Clinical

Molecular subtype

 HER2 positive

12 (12.6%)

96 (16.7%)

36 (22.4%)

144 (17.3%)

 Luminal

71 (74.7%)

394 (68.5%)

103 (64.0%)

568 (68.4%)

 Triple negative

12 (12.6%)

85 (14.8%)

22 (13.7%)

119 (14.3%)

 Missing data

2

0

0

2

Number of death

63

337

75

475

HER2 positive

8

47

8

63

Luminal

42

223

46

311

Triple negative

12

67

21

100

Median between diagnosis and metastatic disease (months)[range]

73.5 [0.7;335.5]

49.0 [0.1;462.5]

57.2 [0.3;322.5]

53.5 [0.1;462.5]

 < 24 months

14 (14.4%)

133 (71.9%)

38 (20.5%)

185 (100%)

 ≥ 24 months

52 (53.6%)

306 (68.9%)

86 (19.4%)

444 (100%)

CA 15.3 [U/ml]

 N

76

449

118

643

 Mean ± sd

338.9 (± 694.6)

212.1 (± 543.0)

198.8 (± 499.4)

224.7 (± 556.2)

 Missing data

21

126

43

190

Lymphocytes [G/l]

 N

73

446

122

641

 Mean ± sd

1.9 (± 1.9)

1.8 (± 1.1)

1.8 (± 1.2)

1.9 (± 1.2)

 Missing data

24

129

39

192

Number of metastatic sites

 < 3 sites

60 (61.9%)

381 (66.3%)

120 (74.5%)

561 (67.3%)

 ≥ 3 sites

37 (38.1%)

194 (33.7%)

41 (25.5%)

272 (32.7%)

Metastatic localization

 Brain

8 (8.2%)

31 (5.4%)

6 (3.7%)

45 (5.4%)

 Bones

70 (72.2%)

400 (69.6%)

105 (65.2%)

575 (69.0%)

 Pulmonary

33 (34.0%)

152 (26.4%)

39 (24.2%)

224 (26.9%)

 Node

31 (32.0%)

189 (32.9%)

57 (35.4%)

277 (33.3%)

 Pleura

19 (19.6%)

59 (10.3%)

17 (10.6%)

95 (11.4%)

 Skin

12 (12.4%)

35 (6.1%)

8 (5.0%)

55 (6.6%)

 Hepatic

33 (34.0%)

202 (35.1%)

51 (31.7%)

286 (34.3%)

 Loco regional

12 (12.4%)

109 (19.0%)

36 (22.4%)

157 (18.8%)

 Others

10 (10.3%)

76 (13.2%)

19 (11.8%)

105 (12.6%)

Adjuvant chemotherapy

 Yes

38 (39.2%)

314 (54.6%)

86 (53.4%)

438 (52.6%)

 No

59 (60.8%)

261 (45.4%)

75 (46.6%)

395 (47.4%)

Dual inhibition of HER2

 Yes

3 (27.3%)

32 (35.6%)

13 (39.4%)

86 (64.2%)

 No

8 (72.7%)

58 (64.4%)

20 (60.6%)

48 (35.8%)

 Missing data

1

6

3

10

Back to article page